StockWatch
·
HomeLiveReports
Filing
Q4

J.B.CHEMICALS & PHARMACEUTICALS LTD.

JBCHEPHARMFY2514 May 2025
Revenue-1.4%
Net Profit-10.3%
OPM23.85%

P&L

Quarterly Consolidated

Revenue
-1.4%949.48
Expenditure
+2.3%770.93
Net Profit
-10.3%145.69
NPM 15.11%-9.7%EPS ₹9.36-10.5%

vs Q3 FY25

JB Chemicals & Pharmaceuticals Ltd Reports 10% Revenue Growth in Q4 FY25 to INR 949 Crores and 12% Growth in FY25 to INR 3918 Crores

14 May 2025 · 14 May 2025, 07:43 pm

Summary

JB Chemicals & Pharmaceuticals Ltd, a fast-growing pharmaceutical company in India, announced its financial results for the quarter and year ended 31st March, 2025. The company reported a 10% increase in revenue to INR 949 crores in Q4 FY25 and a 12% growth in FY25 to INR 3918 crores. The net profit increased by 15% to INR 146 crores in Q4 FY25 and 19% to INR 660 crores in FY25.

Key Highlights

  1. 1

    Domestic business is one of the fastest growing in IPM

  2. 2

    75% of India branded formulations sales in progressive, faster-growing segments

  3. 3

    CDMO business bounced back strongly in second half of the year

  4. 4

    Revenue of INR 949 crores in Q4 FY25, a growth of 10% from Q4 FY24

  5. 5

    Operating EBITDA improved by 15% to INR 240 crores in Q4 FY25

  6. 6

    Net Profit registered growth of 15% to INR 146 crores in Q4 FY25

  7. 7

    Revenue of INR 3918 crores in FY25, a growth of 12% from FY24

  8. 8

    Operating EBITDA increased by 16% to INR 1087 crores in FY25

  9. 9

    Profit after Tax registered growth of 19% to INR 660 crores in FY25

Management Comments

M

Mr. Nikhil Chopra

CEO and Wholetime Director, JB Pharma

We have closed the financial year FY25 on a strong note, in line with our strategic intent and sustained execution in the market. Our Domestic business continues to be one of the fastest growing in IPM. We have built a strong foundation over the last five years. With 75% of India branded formulations sales in progressive, faster-growing segments, we are confident in sustained strong performance going forward. The CDMO business which is another focus area bounced back strongly in second half of the year. Together our Domestic and CDMO business now constitute 69% of overall revenues - Both businesses enjoy high ROCEs & high operating margins and contributed strongly towards enhancing profitability of the organisation.

Informational and educational content only. Not investment advice.